[go: up one dir, main page]

CL2019000198A1 - Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. - Google Patents

Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.

Info

Publication number
CL2019000198A1
CL2019000198A1 CL2019000198A CL2019000198A CL2019000198A1 CL 2019000198 A1 CL2019000198 A1 CL 2019000198A1 CL 2019000198 A CL2019000198 A CL 2019000198A CL 2019000198 A CL2019000198 A CL 2019000198A CL 2019000198 A1 CL2019000198 A1 CL 2019000198A1
Authority
CL
Chile
Prior art keywords
compositions
methods
cannabis
elaboration
tablets
Prior art date
Application number
CL2019000198A
Other languages
English (en)
Inventor
Kurt Levy
Original Assignee
Canopy Growth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61017335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2019000198(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Canopy Growth Corp filed Critical Canopy Growth Corp
Publication of CL2019000198A1 publication Critical patent/CL2019000198A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICIONES QUE COMPRENDEN UN ACEITE QUE TIENE POR LO MENOS UN CANNABINOIDE Y POR LO MENOS UN POLVO SÓLIDO Y MÉTODOS PARA ELABORAR Y USANDO LAS MISMAS. LAS COMPOSICIONES SON APROPIADAS PARA HACER COMPRIMIDOS QUE CONTIENEN CANNABINOIDES PRENSANDO UNA COMPOSICIÓN DE LA PRESENTE INVENCIÓN CON UNO O MÁS AGENTES DE FORMULACIÓN, COMO POR EJEMPLO AGLUTINANTES, CARGAS, AGENTES PARA AUMENTAR EL VOLUMEN, EXCIPIENTES, ETC.
CL2019000198A 2016-07-25 2019-01-25 Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración. CL2019000198A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662366517P 2016-07-25 2016-07-25

Publications (1)

Publication Number Publication Date
CL2019000198A1 true CL2019000198A1 (es) 2019-05-31

Family

ID=61017335

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000198A CL2019000198A1 (es) 2016-07-25 2019-01-25 Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.

Country Status (12)

Country Link
US (3) US20190183850A1 (es)
EP (1) EP3487482A4 (es)
CN (1) CN109789095A (es)
AU (1) AU2017302559A1 (es)
BR (1) BR112019001528A8 (es)
CA (1) CA3031533A1 (es)
CL (1) CL2019000198A1 (es)
CO (1) CO2019000787A2 (es)
IL (1) IL264386B2 (es)
MX (1) MX382609B (es)
PE (1) PE20200478A1 (es)
WO (1) WO2018022669A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3755309A1 (en) * 2018-02-23 2020-12-30 Columbia Care LLC Hard-pressed scored splittable marijuana tablets
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
US20210393573A1 (en) * 2018-10-30 2021-12-23 Kelsie Biotech, Llc Tablets, formulations and methods for low melting point active ingredients
US20220023220A1 (en) * 2019-01-10 2022-01-27 Columbia Care Llc Rapidly disintegrating oral tablet
CA3040547C (en) 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US11633351B2 (en) 2019-12-13 2023-04-25 Nordiccan A/S Fast disintegrating cannabinoid tablets
US10925853B2 (en) 2019-04-17 2021-02-23 Nordiccan A/S Oral cannabinoid tablet
AU2021206021A1 (en) * 2020-01-08 2022-06-02 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
MX2023013814A (es) * 2021-05-21 2024-05-27 Swm Luxembourg Sarl Proceso para incorporar aditivos en sustratos productores de aerosol y productos elaborados a partir de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7908791A (en) * 1990-05-08 1991-11-27 Liposome Technology, Inc. Direct spray-dried drug/lipid powder composition
US6077543A (en) * 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6730330B2 (en) * 2001-02-14 2004-05-04 Gw Pharma Limited Pharmaceutical formulations
JP4467883B2 (ja) * 2001-02-14 2010-05-26 ジーダブリュー・ファーマ・リミテッド 医薬製剤
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
ATE516796T1 (de) * 2006-09-15 2011-08-15 Echo Pharmaceuticals Bv Granulat mit einem pharmazeutischen wirkstoff und einem emulgator und herstellungsverfahren dafür
CN101810593B (zh) * 2010-05-10 2012-07-18 谢恬 一种榄香烯缓释片
US11077086B2 (en) * 2014-07-21 2021-08-03 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
CA2968929A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids

Also Published As

Publication number Publication date
US20210100771A1 (en) 2021-04-08
US20220323403A1 (en) 2022-10-13
IL264386A (en) 2019-02-28
IL264386B2 (en) 2023-08-01
AU2017302559A1 (en) 2019-02-07
WO2018022669A1 (en) 2018-02-01
CO2019000787A2 (es) 2019-04-30
US20190183850A1 (en) 2019-06-20
MX2019001121A (es) 2019-10-21
CA3031533A1 (en) 2018-02-01
IL264386B1 (en) 2023-04-01
BR112019001528A8 (pt) 2019-07-09
BR112019001528A2 (pt) 2019-06-18
EP3487482A4 (en) 2020-03-04
CN109789095A (zh) 2019-05-21
EP3487482A1 (en) 2019-05-29
MX382609B (es) 2025-03-13
PE20200478A1 (es) 2020-03-03

Similar Documents

Publication Publication Date Title
CL2019000198A1 (es) Nuevas formulaciones y composiciones de cannabis en comprimidos y métodos para su elaboración.
MX2024001394A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
CL2017002335A1 (es) Composiciones de cosmetica topica para combatir radicales libres
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
BR112019006194A2 (pt) composições que compreendem um ligante de ligação ao receptor de canabinóides
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
UY36950A (es) Compuestos útiles como inhibidores de la interacción proteína-proteína pd-1/pd-l1 y cd80/pd-l1 y composiciones que los contienen
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MX2017015083A (es) Composiciones cosmeticas que comprenden e/z-bencilideno-5,6-dimeto xi-3,3-dimetilindan-1-ona.
MX2016014509A (es) Formulacion de vitamina soluble en grasa.
UY36705A (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
MX2018007155A (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj).
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
PE20200223A1 (es) Una composicion bioestimulante a base de taninos y/o sus derivados, para el tratamiento de plantas cultivadas y/o partes de las mismas
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
AR108616A1 (es) Formulación combinada de tres compuestos antivirales
BR112017018618A2 (pt) odorizante de osmanthus
MX391331B (es) Composiciones de microesferas de gas encapsuladas en lipidos y metodos relacionados.